Managing mCRC

CE / CME

Opportunities and Challenges in Management of Metastatic Colorectal Cancer

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: May 02, 2023

Expiration: May 01, 2024

Activity

Progress
1
Course Completed

Which of the following is the significance of dMMR/MSI-H in selecting therapy for mCRC?

Which of the following is a characteristic of immune-related adverse events associated with anti-PD-1 ICI therapy?

Which of these is the recommended second-line option for patients with BRAFV600E-mutated mCRC?

Sarah is receiving pembrolizumab to treat unresectable mCRC. She develops grade 1 immune-related colitis after 2 cycles, with 3-4 bouts of diarrhea daily. What would be your recommendation for management?

Max, 75, has mCRC with progression after 1L chemotherapy + bevacizumab. His molecular profile is MSS, RAS WT, BRAF WT, and HER2+ (ERBB+ on NGS). Which of these is a recommended option for his next therapy?

How often do you currently ensure that patients with mCRC are undergoing recommended molecular testing?

How often do you currently recommend 1L chemotherapy + EGFR inhibitor for patients with newly diagnosed, left-sided RAS/BRAF wild-type mCRC?

How often do you currently monitor renal and hepatic function in patients with mCRC prior to each infusion of pembrolizumab?

Sarah, 46, has been diagnosed with unresectable mCRC. Her molecular profile is dMMR/MSI-H, BRAFV600E+, RAS WT, and HER2 and NTRK negative. Which of these is the recommended initial treatment option for her?

References

  1. American Cancer Society. Cancer facts & figures 2023. www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html. Accessed March 16, 2023.
  2. Cancer.Net. Colorectal cancer: statistics. www.cancer.net/cancer-types/colorectal-cancer/statistics. Accessed March 16, 2023.
  3. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force Recommendation. JAMA. 2021;325:1965.
  4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: colon cancer. V.3.2022. www.nccn.org. Accessed March 16, 2023. 
  5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: rectal cancer. V.4.2022. www.nccn.org. Accessed March 16, 2023.
  6. Salem ME, Puccini A, Tie J. Redefining colorectal cancer by tumor biology. Am Soc Clin Oncol Educ Book. 2020;40:1-13.
  7. Djaballah SA, Daniel F, Milani A, et al. HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target. Am Soc Clin Oncol Educ Book. 2022;42:219.
  8. Tabernero J, Ros J, Élez E. The evolving treatment landscape in BRAFV600E-mutated metastatic colorectal cancer. Am Soc Clin Oncol Educ Book. 2022; 42:1-10.
  9. Bhattacharya P, McHugh TW. Lynch syndrome. StatPearls. www.ncbi.nlm.nih.gov/books/NBK431096. Accessed March 16, 2023. 
  10. Yurgelum MB, Hampel H. Recent advances in Lynch syndrome: diagnosis, treatment, and cancer prevention. Am Soc Clin Oncol Educ Book. 2018;38:101-109.
  11. Niu M, Chen C, Gao X, et al. Comprehensive analysis of the differences between left- and right-side colorectal cancer and respective prognostic prediction. BMC Gastroenterology. 2022;22:482.
  12. Morris VK, Kennedy EB, Baxter NN, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023;41:678. 
  13. Vogel A, Hofheinz RD, Kubicka S, et al. Treatment decisions in metastatic colorectal cancer: beyond first and second line combination therapies. Cancer Treat Rev. 2017;59:54.
  14. Yoshino T, Watanabe J, Shitara K, et al. Panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type metastatic colorectal cancer: results from the phase 3 PARADIGM trial. J Clin Oncol. 2022;40. Abstract LBA1.
  15. Heinemann V, Fischer von Weikersthal L, Decker T, et al. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomized clinical trial. Br J Cancer. 2021;124:587. 
  16. Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659.
  17. André T, Amonkar M, Norquist JM, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomized, phase 3 trial. Lancet Oncol. 2021;22:665. 
  18. André T, Lonardi S, Wong KYM, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.  Ann Oncol. 2022;33:1052. 
  19. Lenz HJ, Van Cutsem E, Limon ML, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase II CheckMate 142study. J Clin Oncol. 2022;40:161.
  20. Pembrolizumab [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2023.
  21. Nivolumab [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2022.
  22. Dostarlimab-gxly [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2021.
  23. National Comprehensive Cancer Network. Management of immunotherapy-related toxicities. V.1.2023. www.nccn.org. Accessed March 16, 2023. 
  24. Wood LS. Immune-related adverse events from immunotherapy: incorporating care step pathyways to improve management across tumor types. J Adv Pract Oncol. 2019;10(suppl):47.
  25. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune checkpoint inhibitors: epidemiology, management, and surveillance. Nature Rev. 2019;16:563.
  26. Wang DY, Ye F, Zhao S, et al. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systemtic review and meta-analysis. Oncoimmunol. 2017;6:e1344805.
  27. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714.
  28. Dougan M, Blidner AG, Choi J, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal hepatic toxicities from checkpoint inhibitors. Support Care Cancer. 2020;28:6129.
  29. Li Y, Kang X, Wang H, et al. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. Thoracic Cancer. 2020;11:829.
  30. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073.
  31. Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroups analysis from the BEACON study. J Clin Oncol. 2021;39:273.  
  32. Meric-Bernstam F, Hainsworth J, Bose R, et al. MyPathway HER2 basket study: pertuzumab + trastuzumab treatment of a large tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. J Clin Oncol. 2021;39. Abstract 3004. 
  33. Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket trail. Lancet Oncol. 2019;20:518-530.
  34. Siena S, Di Bartolomeo M, Raghav KPS, et al. Trastuzumab dertuxtecan in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicenter, open-label, phase 2 trial. Lancet Oncol. 2021;22:779.
  35. Strickler JH, Cercek A, Siena S, et al. Additional analyses of MOUNTAINEER: a phase II study of tucatinib and trastuzumab for HER2-positive mCRC. Ann Oncol. 2022;33. Abstract LBA27. 
  36. Strickler JH, Ng K, Cercek A, et al. MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017). J Clin Oncol. 2021;39. Abstract TPS153. 
  37. Tosi F, Sartore-Bianchi A, Lonardi S, et al. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin Colorectal Cancer. 2020;19:256.
  38. Yoshino T, Di Bartolomeo M, Raghav KPS, et al. Trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer: final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). J Clin Oncol. 2022;40. Abstract 119.
  39. Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2022.
  40. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:271-282.
  41. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21:531-540.
  42. Entrectinib [prescribing information]. South San Francisco, CA: Genentech USA; 2022.
  43. Larotrectinib [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2022.
  44. Subbiah V, Wolf J, Konda B, et al. Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: a global, multicenter, registrational trial update (LIBRETTO-001). J Clin Oncol. 2022;40. Abstract 3094. 
  45. Subbiah V, Wolf J, Konda B, et al. Tumor-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumors other than lung or thyroid tumors (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022;23:1261.
  46. Selpercatinib [prescribing information]. Indianapollis, IN: Lilly USA, LLC; 2022
  47. Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancer with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022;23:115.
  48. Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;388:44.
  49. Tabernero J, Prager GW, Fakih M, et al. Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized SUNLIGHT study.  Presented at: 2023 ASCO Gastrointestinal Cancers Symposium; January 18-20, 2023. Abstract 4.
  50. Bekaii-Saab T, Kim R, Kim TW, et al. Third- or later-line therapy for metastatic colorectal cancer: reviewing best practice. Clin Colorectal Cancer. 2019;18:e117-e129.
  51. Pfeiffer P, Yilmaz M, Möller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomized, phase 2 trial. Lancet Oncol. 2020;21:412.
  52. Regorafenib [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2020.
  53. Goey KK, Elias SG, van Tinteren H, et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann Oncol. 2017;28:2128. 
  54. Kasi PM. Treatment holidays for patients with metastatic colorectal cancer. J Clin Oncol. 2021;39:3656.